Revvity (NYSE:RVTY) Price Target Raised to $124.00 at TD Cowen

Revvity (NYSE:RVTY) had its price target lifted by TD Cowen from $120.00 to $124.00 in a research report sent to investors on Tuesday morning, Marketbeat reports. TD Cowen currently has a buy rating on the stock.

RVTY has been the topic of a number of other reports. Wells Fargo & Company increased their price target on Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Guggenheim assumed coverage on shares of Revvity in a report on Wednesday, October 15th. They issued a “neutral” rating on the stock. The Goldman Sachs Group initiated coverage on shares of Revvity in a research report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 target price for the company. Barclays boosted their price objective on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Robert W. Baird raised their target price on Revvity from $122.00 to $123.00 and gave the company an “outperform” rating in a research report on Tuesday, October 28th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $113.67.

Revvity Stock Performance

Revvity stock opened at $100.85 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.44. Revvity has a 12 month low of $81.36 and a 12 month high of $124.82. The company has a fifty day moving average price of $103.99 and a two-hundred day moving average price of $95.57. The company has a market cap of $11.43 billion, a PE ratio of 48.49, a P/E/G ratio of 3.22 and a beta of 1.07.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business had revenue of $772.06 million during the quarter, compared to analyst estimates of $759.81 million. During the same period in the previous year, the business posted $1.42 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Research analysts expect that Revvity will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be given a $0.07 dividend. The ex-dividend date is Friday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s payout ratio is 14.07%.

Revvity announced that its board has approved a share repurchase program on Monday, October 27th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 8.7% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently modified their holdings of RVTY. AQR Capital Management LLC lifted its holdings in shares of Revvity by 5.2% during the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after purchasing an additional 420 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Revvity by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock worth $1,246,000 after buying an additional 744 shares during the period. Millennium Management LLC lifted its stake in Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock valued at $7,343,000 after buying an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Revvity by 45.5% in the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after buying an additional 189,871 shares during the period. Finally, Focus Partners Wealth increased its position in shares of Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after acquiring an additional 811 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported stronger-than-expected Q4 results: adjusted EPS $1.70 (above estimates) and revenue $772.1M (+5.9% YoY). Management raised FY‑2026 guidance (EPS $5.35–5.45; revenue ~ $3.0B), which sits slightly above consensus. These beats and the raised guidance are the primary fundamental positives supporting the stock. Reuters: Revvity forecasts 2026 profit, revenue above estimates
• Positive Sentiment: Multiple analysts lifted price targets after the results — TD Cowen to $124 (buy), Wells Fargo to $110 (equal weight), and JPMorgan to $105 (neutral) — signaling continued analyst support and upside in some research houses. The Fly: TD Cowen raise Benzinga: analyst notes
• Neutral Sentiment: Full earnings call transcript, slide deck and presentation are available for deeper review — useful for assessing segment trends (diagnostics strength vs. academic research weakness) but neutral until investors digest details. Seeking Alpha: Q4 transcript
• Neutral Sentiment: Analyst/market commentary highlights Revvity as a momentum name and reviews key metrics vs. estimates — useful framing for traders but not new primary drivers. Zacks: momentum piece
• Negative Sentiment: Despite the positive news, shares fell today — trading volume was above average — suggesting profit-taking, short‑term rotation, or valuation concerns (RVTY’s trailing P/E is elevated). The market may be pricing a higher bar for sustained upside even after the beat and upgrades.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.